Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease.
ABSTRACT Macrophages are principal drivers of synovial inflammation in rheumatoid arthritis (RA), a prototype immune-mediated inflammatory disease. Conceivably, synovial macrophages are continuously replaced by circulating monocytes in RA. Animal studies from the 1960s suggested that macrophage replacement by monocytes is a slow process in chronic inflammatory lesions. Translation of these data into the human condition has been hampered by the lack of available techniques to analyze monocyte migration in man.
We developed a technique that enabled us to analyze the migration of labelled autologous monocytes in RA patients using single photon emission computer tomography (SPECT). We isolated CD14+ monocytes by CliniMACS in 8 patients and labeled these with technetium-99m (99mTc-HMPAO). Monocytes were re-infused into the same patient. Using SPECT we calculated that a very small but specific fraction of 3.4 x 10(-3) (0.95-5.1 x 10(-3)) % of re-infused monocytes migrated to the inflamed joints, being detectable within one hour after re-infusion.
The results indicate monocytes migrate continuously into the inflamed synovial tissue of RA patients, but at a slow macrophage-replacement rate. This suggests that the rapid decrease in synovial macrophages that occurs after antirheumatic treatment might rather be explained by an alteration in macrophage retention than in monocyte influx and that RA might be particularly sensitive to treatments targeting inflammatory cell retention.
- SourceAvailable from: Sergio Augusto Lopes de Souza[Show abstract] [Hide abstract]
ABSTRACT: Rheumatoid arthritis (RA) is an autoimmune disease, which is associated with systemic and chronic inflammation of the joints, resulting in synovitis and pannus formation. For several decades, the assessment of RA has been limited to conventional radiography, assisting in the diagnosis and monitoring of disease. Nevertheless, conventional radiography has poor sensitivity in the detection of the inflammatory process that happens in the initial stages of RA. In the past years, new drugs that significantly decrease the progression of RA have allowed a more efficient treatment. Nuclear Medicine provides functional assessment of physiological processes and therefore has significant potential for timely diagnosis and adequate follow-up of RA. Several single photon emission computed tomography (SPECT) and positron emission tomography (PET) radiopharmaceuticals have been developed and applied in this field. The use of hybrid imaging, which permits computed tomography (CT) and nuclear medicine data to be acquired and fused, has increased even more the diagnostic accuracy of Nuclear Medicine by providing anatomical localization in SPECT/CT and PET/CT studies. More recently, fusion of PET with magnetic resonance imaging (PET/MRI) was introduced in some centers and demonstrated great potential. In this article, we will review studies that have been published using Nuclear Medicine for RA and examine key topics in the area.World journal of orthopedics. 07/2014; 5(3):312-8.
- [Show abstract] [Hide abstract]
ABSTRACT: OBJECTIVE. A review of the innovative role molecular imaging plays in musculoskeletal radiology is provided. Musculoskeletal molecular imaging is under development in four key areas: imaging the activity of osteoblasts and osteoclasts, imaging of molecular and cellular biomarkers of arthritic joint destruction, cellular imaging of osteomyelitis, and imaging generators of musculoskeletal pain. CONCLUSION. Together, these applications suggest that next-generation musculoskeletal radiology will facilitate quantitative visualization of molecular and cellular biomarkers, an advancement that appeared futuristic just a decade ago.American Journal of Roentgenology 06/2013; · 2.90 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Dendritic cells (DCs) are highly efficient antigen-presenting cells. The migratory properties of DCs give them the capacity to be a sentinel of the body and the vital role in the induction and regulation of adaptive immune responses. Therefore, it is important to understand the mechanisms in control of migration of DCs to lymphoid and nonlymphoid tissues. This may provide us novel insight into the clinical treatment of diseases such as autoimmune disease, infectious disease, and tumor. The chemotactic G protein-coupled receptors (GPCR) play a vital role in control of DCs migration. Here, we reviewed the recent advances regarding the role of GPCR in control of migration of subsets of DCs, with a focus on the chemokine receptors. Understanding subsets of DCs migration could provide a rational basis for the design of novel therapies in various clinical conditions.BioMed research international. 01/2014; 2014:738253.
Monocyte Scintigraphy in Rheumatoid Arthritis: The
Dynamics of Monocyte Migration in Immune-Mediated
Rogier M. Thurlings1, Carla A. Wijbrandts1, Roelof J. Bennink2, Serge E. Dohmen3, Carlijn Voermans3,
Diana Wouters4, Elena S. Izmailova5, Danielle M. Gerlag1, Berthe L. F. van Eck-Smit2, Paul P. Tak1*
1Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Noord Holland, The Netherlands,
2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Noord Holland, The Netherlands, 3Landsteiner Laboratory,
Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Noord Holland, The Netherlands, 4Department of Immunopathology, Sanquin
Research, Amsterdam, Noord Holland, The Netherlands, 5Millennium Pharmaceuticals, Inc, Department of Research and Development, Cambridge, Massachusetts, United
States of America
Background: Macrophages are principal drivers of synovial inflammation in rheumatoid arthritis (RA), a prototype immune-
mediated inflammatory disease. Conceivably, synovial macrophages are continuously replaced by circulating monocytes in
RA. Animal studies from the 1960s suggested that macrophage replacement by monocytes is a slow process in chronic
inflammatory lesions. Translation of these data into the human condition has been hampered by the lack of available
techniques to analyze monocyte migration in man.
Methods/Principal Findings: We developed a technique that enabled us to analyze the migration of labelled autologous
monocytes in RA patients using single photon emission computer tomography (SPECT). We isolated CD14+ monocytes by
CliniMACS in 8 patients and labeled these with technetium-99m (99mTc-HMPAO). Monocytes were re-infused into the same
patient. Using SPECT we calculated that a very small but specific fraction of 3.461023(0.9525.161023) % of re-infused
monocytes migrated to the inflamed joints, being detectable within one hour after re-infusion.
Conclusions/Significance: The results indicate monocytes migrate continuously into the inflamed synovial tissue of RA
patients, but at a slow macrophage-replacement rate. This suggests that the rapid decrease in synovial macrophages that
occurs after antirheumatic treatment might rather be explained by an alteration in macrophage retention than in monocyte
influx and that RA might be particularly sensitive to treatments targeting inflammatory cell retention.
Citation: Thurlings RM, Wijbrandts CA, Bennink RJ, Dohmen SE, Voermans C, et al. (2009) Monocyte Scintigraphy in Rheumatoid Arthritis: The Dynamics of
Monocyte Migration in Immune-Mediated Inflammatory Disease. PLoS ONE 4(11): e7865. doi:10.1371/journal.pone.0007865
Editor: Andrew Boswell, Genentech, United States of America
Received April 22, 2009; Accepted July 31, 2009; Published November 17, 2009
Copyright: ? 2009 Thurlings et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by Millenium Pharmaceuticals, Inc. This company participated in the design of the study, performed the pre-clinical in vitro
experiments concerning monocyte activation, monitored the clinical study and approved the manuscript. Millenium Pharmaceuticals, Inc. participated in the
analysis and interpretation of the clinical study and in the preparation of the manuscript. All authors were involved in the study design, had access to all data,
were responsible for the decision to publish, and prepared the manuscript.
Competing Interests: Millennium Pharmaceuticals Inc. (Cambridge, Massachusetts) was involved in the study design and supported the study. Millennium does
not hold any IP (patent) applications with claims relevant to the materials or assays described in the manuscript. Millennium might consider using the monocyte
scan described in the manuscript for the evaluation of novel antirheumatic drugs in the future.
* E-mail: email@example.com
Macrophages in the inflamed synovial tissue of rheumatoid
arthritis (RA) patients play a central role in the sustenance of
synovial inflammation and promotion of tissue destruction [1–3].
Conceivably they are continuously replaced by circulating
monocytes . The dynamics of this replacement is a matter of
controversy. Data on the effects of anti-rheumatic treatments
suggest this might be a highly dynamic process [5–11], while
animal studies from the 1960s suggested it might occur at a slow
Newly developed imaging techniques, such as Single Photon
emission Computed Tomography (SPECT), Positron Emission
Tomography (PET) and more recently bioluminescence and
fluorescence reflectance imaging, offer the possibility to portray
the in vivo dynamics of cell migration in patients . The
application of these imaging modalities to analyze the behavior of
monocytes is hampered by the relative scarcity of these cells in the
peripheral blood and the technical difficulties of specific cell
isolation at the GMP level and efficient labeling to result in an
adequate detection signal. These problems might be addressed by
the combination of scintigraphic imaging with sophisticated cell
isolation procedures, such as immunomagnetic cell selection .
We recently developed a procedure using a combination of
immunomagnetic cell selection with CD14 coated beads and an
improved labeling procedure with technetium-99m (99mTc)-
hexamethylpropylene-amino-oxime (HMPAO) and SPECT to
visualize the migratory behavior of autologous monocytes [18,19].
PLoS ONE | www.plosone.org1 November 2009 | Volume 4 | Issue 11 | e7865
We applied this method in patients with active RA to test the
hypothesis that synovial inflammation is maintained by a
continuous influx of monocytes into the synovial compartment
and to analyze the dynamics of such influx.
Eight RA patients (4 male and 4 female) were included into the
study. The median age of the patients was 52 years (range 39 to 59
years) and the mean disease duration was 19 (range 10–38) years.
Erosions were present in all patients. Two patients had nodular
disease. Four patients were seropositive for IgM rheumatoid
factor. The mean (6SD) disease activity score evaluated in 28
joints (DAS28) at screening was 5.860.8. All patients were treated
with stable dosages of methotrexate.
Applying immunomagnetic cell selection with CD14 labeled
beads, on average 19.96106(10.4236.96106) monocytes were
isolated, with a mean recovery of 40.8% (24–69%) CD14 positive
cells. This resulted in a cell suspension with a purity of 90.4% (79–
96%) CD14 positive cells as determined by FACS analysis.
Labeling with99mTc-HMPAO resulted in a mean radioactivity of
211 (43–393) MBq. Having shown that CD62L expression on
monocytes did not change after the bead isolation procedure and
migratory capacity in vitro (unpublished observations), we decided
to re-infuse labeled monocytes in RA patients. Re-infusion was
well tolerated in all patients. No signs of increased complement
activation could be demonstrated one hour after re-infusion of
radioactively labeled monocytes: C3b/c (mean6SD): 26.4613.5
99mTc-HMPAO labeling did not affect the monocyte
and C4b/c 8.361.5 before treatment versus 26.0612.3 and
16.2610.0 1 hour after re-infusion, respectively).
Migration of labeled monocytes was visualized using scintigraphy.
by redistribution in liver, spleen and bone marrow (Figure 1),
following the pattern of labeled leukocytes . As expected, renal
activity with visualization of the urinary bladder was seen in all
patients. Furthermore, physiological bowel uptake could be detected
from one hour post infusion. Significant uptake of radioactivity in
stomach and/or thyroid was not observed. In 2 patients whole-body
imaging was feasible up to 20 hours post infusion.
Small but distinct uptake was found in the joints of all patients,
with a mean of 9 (range 1–25) positive joints (Figures 1 and 2).
There was an increased signal in di-arthrodial joints in all patients
at all time points, with a maximal signal at one hour post re-
infusion (Figure 3). We calculated that a median of 4827
(interquartile range [IQR] 2094–8370) labeled monocytes migrat-
ed into the biopsied joints that were analyzed in more detail,
representing 3.461023(0.9525.161023) % of re-infused mono-
cytes. The results were confirmed after 2 weeks, when the scans
were repeated: there was no change in clinical parameters, the
number of joints with increased signal on the scintigraphic images,
and joint signal intensity. Using these numbers, an estimate was
made about the extent of monocyte influx into the biopsied joints.
The median monocyte concentration in peripheral blood was
(1.622.36109) at the time of blood withdrawal.
Assuming an average blood volume of 5 liters, a median of
323.000 (272.000–1.150.000) monocytes entered the biopsied
joints (3.461023% of total circulating monocytes).
Figure 1. Scintigraphic images of labeled autologous monocytes in a patient with rheumatoid arthritis. Anterior and posterior (A,B)
whole body images of a patient 2 hours after infusion of monocytes labeled with 283 MBq99mTc-HMPAO. Transient pulmonary accumulation occurs,
with an equivalently increased uptake in liver, spleen and bone marrow (A,B). A reference source is placed just below the knees. Panel C and D show
the same images but with masking of the pulmonary, bladder and source signal. Increased articular uptake is observed in di-arthrodial joints as the
shoulders, elbows, knees and small hand joints.
Monocyte Scintigraphy in RA
PLoS ONE | www.plosone.org2 November 2009 | Volume 4 | Issue 11 | e7865
Since macrophages are the dominant synovial inflammatory cell
population and the extent of their tissue infiltration correlates with
disease activity [1–3,20], we compared scintigraphic signal intensity
with synovial macrophage infiltration and disease activity param-
eters. Synovial macrophage infiltration was assessed by immuno-
histochemical staining of arthroscopic biopsies from selected joints.
These biopsy samples had been obtained one day after the second
scintigraphy. Six out of 8 synovial biopsies passed synovial tissue
quality control. The number of CD163 positive macrophages in the
synovium correlated significantly with the number of scintigraphy
positive joints one, two and three hours after re-infusion (r=0.89,
P=0.019; r=0.89, P=0.019; r=0.94, P,0.01, respectively).
Furthermore, there was a significant correlation between the
number of CD163 positive macrophages and the percentage of
monocytes shown by scintigraphy two hours after re-infusion
(r=0.89, P=0.019). The other immunohistologic markers were not
significantly correlated with scintigraphic data (data not shown).
Subsequently, the relationship between scintigraphic signal and
disease activity parameters was analyzed. Of interest, the swollen
in the biopsied joints selected for detailed quantification on the
images that were taken one and two hours after re-infusion (day 1:
r=0.97 and r=0.73, respectively; P,0.01, day 14: r=0.78 and
r=0.90; P,0.01). There was also a positive correlation between the
number of swollen joints and the number of positive joints shown by
scintigraphic scans at day 14 (r=0.81, r=0.76 and r=0.81; all
P,0.01, at respectively 1, 2 and 3 hours after infusion).
In the present study we used a recently developed procedure,
that visualizes the migratory behavior of monocytes [18,19], to test
the hypothesis that synovial inflammation in RA is maintained by
influx of monocytes into the synovial compartment. The results
suggest that while there is indeed a continuous influx of circulating
monocytes into the synovial compartment, their numbers are
small, indicating that only a relatively small fraction of synovial
macrophages is replaced per day.
We found that a median of 3.461023(0.9525.161023) % of
labelled monocytes entered the synovial compartment after re-
Figure 2. Scintigraphic detail images of hands and feet of labeled autologous monocytes in a patient with rheumatoid arthritis.
Scintigraphic detail images of hands in palmar position (A–C) and feet in plantar position (D,E) and anterior position (F) of RA patients 2 h after
infusion of monocytes labeled with 99mTc-HMPAO. Images of the hands show increased uptake in the wrists, MCP and IP joints (A–C). Images of the
feet show increased uptake of the ankle, tarsus, MTP and IP joints (D–F).
Monocyte Scintigraphy in RA
PLoS ONE | www.plosone.org3 November 2009 | Volume 4 | Issue 11 | e7865
infusion. Since we found no indication that the monocytes were
activated by the labelling or isolation procedures, this suggests that
similar percentages of unlabeled circulating monocytes enter the
synovial compartment, being a median of 323.000 cells. Since the
number of synovial macrophages in large inflamed joints exceeds
such numbers considerably, these data indicate that in RA patients
the rate of synovial macrophage renewal by circulating monocytes
It was recently shown that a range of anti-rheumatic treatments
induces a significant decrease in synovial macrophages associated
with clinical improvement within hours to weeks after initiation of
therapy [5,6]. It was hypothesized that these treatments ultimately
affect migration of monocytes and/or retention of macrophages
. In studies on infliximab, an effective biological treatment for
RA which blocks TNFa , a marked decrease in synovial
macrophage numbers occurred already 24 hours after initiation of
treatment, which could not be explained by induction of apoptosis
[8–11]. The results of the current study suggest that this effect may
mostly explained by an effect of TNFa blockade on macrophage
retention. Of interest, a decrease in VCAM-1 and ICAM was
found shortly after infliximab treatment [8,10]. While these are
important molecules involved in adhesion of monocytes to the
vascular endothelium, they are in RA patients also abundantly
expressed by cells in the intimal lining layer and the synovial
sublining, where they play a pivotal role in inflammatory cell
retention and survival .
Thus, the data indicate that in line with animal models on
chronic inflammatory lesions, macrophage renewal by monocytes
is slow in chronic synovitis [12–15]. Together with the previous
studies showing a rapid decrease in cellularity after successful
antirheumatic therapy (even in the absence of apoptosis), these
data support the notion that therapeutic strategies aimed at
interfering with retention of inflammatory cells at the site of
inflammation might be capable of inducing clinical improvement
in immune-mediated inflammatory disease. Accordingly, recent
studies have shown benefit of interfering with adhesion molecules:
anti-function associated antigen (LFA)-1 antibody (efalizumab)
treatment in psoriasis and anti-a4b1-integrin (VLA-4) antibody
(natalizumab) treatment in multiple sclerosis [24,25].
In conclusion, we developed monocyte scintigraphy, which allowed
us to demonstrate the dynamic influx of monocytes into the synovial
compartment of RA patients. This approach provides insight into the
pathogenesis of this immune-mediated inflammatory disease and
supports the notion that blocking only the influx of inflammatory cells
may be insufficient to induce clinical improvement.
Materials and Methods
Patients fulfilling the American College of Rheumatology (ACR)
1987 revised classification criteria for RA  were included into
the study. All patients had active RA, as defined by a disease
activity score evaluated in 28 joints (DAS28) .3.2 . Patients
were on stable disease-modifying antirheumatic drug (DMARD)
treatment at inclusion.
Approval was granted by the Medical Ethics Committee of the
Academic Medical Center/University of Amsterdam (AMC).
Each patient gave written informed consent prior to participation.
Isolation of Monocytes
Hundred milliliters of peripheral blood was taken from each
patient. CD14+ monocytes were isolated using a positive selection
procedure with magnetic-activated cell sorting according to the
manufacturer’s protocol (MACSHMiltenyi Biotech, Bergisch Glad-
bach, Germany). After selection, the percentage of CD14, CD3,
and CD66 positive cells was determined by fluorescence-activated
cell sorting (FACS) analysis. The CD14+ enriched cells were
resuspended in 10 ml buffer containing 0.9% (w/v) NaCl, 20% (w/
v) human serum albumin (Sanquin Blood Supply Foundation
division of Plasma Products, Amsterdam, the Netherlands) and
3.8% (w/v) TNC (NVI, Bilthoven, the Netherlands) for labeling.
Exametazime (CeretecTM, RVG16226) was supplied as a ready-
for-labeling kit (GE Healthcare B.V., Amersham, Cygne Centre,
Eindhoven, the Netherlands).99mTc-pertechnetate was obtained
4329, Tyco Healthcare, Mallinckrodt Medical, Petten, the
Netherlands) and was eluted in accordance with the instructions
of the manufacturer. Radiochemical purity control (RPC) assays
were done by means of chromatography on ITLC-SG strips, using
a mobile phase of 0.9% sodium chloride (NaCl) . Radiolabel-
ing of cells was performed as described earlier . Briefly, the
cells were centrifuged and freshly prepared
very high specific activity in a low volume was added to the
monocyte cell pellet. After incubation the excess of
HMPAO was diluted and subsequently removed from the cell
pellet after centrifugation. The labeled monocytes were resus-
pended in 0.9% NaCl and re-infused into the same patient.
99Mo-carrying UltratechnekowH FM generator (DRN
An average of 206106monocytes labeled with 200 MBq99mTc-
HMPAO was injected intravenously within 15 minutes after
radiolabeling. Whole body imaging was performed at 15 minutes
and 1, 2, 3, and 20 hours post infusion using a dual head
gammacamera (140 keV, window 15%, 25661024 matrix,
10 cm/min) fitted with low energy all purpose collimators
(Siemens Ecam). Detail images of the hands (palmar) and feet
(plantar) were acquired in a 2566256 matrix for 5 minutes. This
procedure was repeated two weeks after the baseline scintigraphy.
Figure 3. Percentage of re-infused monocytes in a joint in time.
Detailed signal intensity calculation of percentage of re-infused
monocytes in a selected joint of the individual patients in time after
infusion. A stable presence of monocytes in the joints is visible.
Monocyte Scintigraphy in RA
PLoS ONE | www.plosone.org4November 2009 | Volume 4 | Issue 11 | e7865
The scintigraphic scans were analyzed for signal intensity in
joints and other tissues. The number of positive joints and the
exact signal intensity of the biopsied joint was selected for more
detailed quantification. The signal intensity was calculated in
counts per region of interest, subtracting the background signal
from the joint signal. A correction was made for the number of re-
infused monocytes and the injected dose, using a standard dose
source, leading to a deduction of the percentage of re-infused
monocytes per ROI.
In Vitro Assays to Determine the Influence of Isolation
and Labeling on Monocyte Migratory Function and
Monocytes were isolated from whole blood of subjects and
migratory function was assessed by in vitro chemotaxis assay
comparing radioactively labeled and non-labeled cells. Briefly,
chemotaxis assay was done using 24-well chemotaxis plates
(Corning Costar, Corning, NY) with inserts containing pre-grown
ECV304 cells. Purified monocytes were re-suspended in 600 ul of
pre-warmed RPMI medium containing 3% fetal calf serum
(GIBCO, BRL) and added to the upper chamber of the transwell
plate. Chemotaxis was performed for 2 hours at 37uC against
various concentrations of recombinant MCP-1 (R&D Systems,
Minneapolis, MN). Cell migration rate was quantified by flow
cytometry for non-labeled monocytes and scintillation gamma
counter for labeled monocytes. Comparison of migrating cell
percentage for non-labeled and Tc- HMPAO labeled monocytes
did not demonstrate an impairment of monocyte migratory
capacity in the in vitro chemotaxis assay (data not shown).
Monocyte activation was tested by assessing CD62L expression
after the bead isolation procedure using CD62L-PE conjugated
antibody (BD Biosciences). Antibody concentrations were used
according the manufacturer’s protocol. Antibody staining was
performed using 50 ml of whole blood. Blood cells were incubated
with antibodies for 15 min and washed twice with PBS containing
1% bovine serum albumin (Sigma-Aldrich, MO). Red cells were
lysed by washing cells twice with BD FACSTMlysis solution (BD
Biosciences, CA). Purified monocytes were resuspended in PBS
containing 1% bovine serum albumin (Sigma-Aldrich, MO),
incubated with antibody and fixed with FACSTMlysis solution
(BD Biosciences, CA). Samples were analyzed by flow cytometry
using a FACS Calibur (Becton Dickinson, NJ). Frequency of
CD62L expression on monocytes did not change after the bead
isolation procedure (data not shown).
In Vivo Assessment of Complement Activation after
To exclude the possibility that re-infusion of labeled monocytes
induced complement activation, complement activation products
were measured in the serum before and one hour after re-infusion.
Activation of C3 (C3b/c) and C4 (C4b/c) was assessed with an
ELISA as described before in detail . In brief, monoclonal
antibodies recognizing neo-epitopes on activated C3 and C4 were
used as capturing antibodies. Biotinylated polyclonal rabbit anti-
human C3 and polyclonal sheep anti-human C4 antibodies were
used as detecting antibodies.
Arthroscopy and Synovial Biopsy
The day after the second set of scans, all patients underwent a
mini-arthroscopy under local anesthesia from an actively inflamed
knee, ankle or wrist, to obtain synovial tissue samples . Biopsies
were taken with a 2.3-mm grasping forceps (Storz, Tuttlingen,
Germany) from 6 or more sites within the joint to minimize sampling
error. The tissue samples were snap frozen en bloc in Tissue Tek
OCT (Miles, Elkhart, IN) after collection. Frozen blocks were stored
in liquid nitrogen until sectioning. Sections of 5 mm were cut using a
cryostat and mounted on Star Frost adhesive glass slides (Knittelgla ¨-
ser, Braunschweig, Germany). Sealed slides were stored at 280uC
until immunohistochemical staining was performed.
Synovial tissue sections were stained using the following
monoclonal antibodies to analyze the cell infiltrate: anti-CD55
(67:Serotec, Oxford, UK) to detect fibroblast-like synoviocytes
(FLS), anti-CD68 (EBM11: DAKO, Glostrup, Denmark) to detect
macrophages and anti-CD3 (SK7, Becton Dickinson, San Jose, CA)
for T-cells as described previously . The scavenger receptor
CD163 (Ber-MAC3; DAKO) was stained to detect alternatively
activated tissue macrophages. Staining of cellular markers was
performed using a three-step immunoperoxidase method . For
control sections the primary antibody was omitted or irrelevant
immunoglobulins were applied. Tissue quality was assessed by
analyzing the presence of an intimal lining layer.
Digital Image Analysis
All sections were analyzed at random by trained technicians
who were blinded for clinical and scintigraphic data. The analysis
was done by computer-assisted image analysis as previously
described in detail (323). In short, images were acquired and
analyzed using a Syndia algorithm on a Qwin-based analysis
system (Leica, Cambridge, UK). For all markers 18 high-power
fields were analyzed. Positive staining of cellular markers was
expressed as positive cells per mm2(counts/mm2). CD68+
macrophages were analyzed separately for the intimal lining layer
and the synovial sublining.
Associations between joint signal parameters and swollen joint
count, tender joint count, DAS28, ESR, CRP and immunohisto-
chemical markers were expressed by Spearman’s correlation
coefficients. The changes in joint signal intensity and clinical
parameters after two weeks were tested with the Wilcoxon signed
ranks test for paired non-parametric data.
We thank the clinical team of the Department of Clinical Immunology and
Rheumatology, and Nuclear Medicine and the staff of the Laboratory for
Stem Cell Transplantation at Sanquin Research for their assistance.
Conceived and designed the experiments: RMT CAW RJB SED CV DW
ESI DMG BLFvES PPT. Performed the experiments: RMT CAW RJB
SED CV DW. Analyzed the data: RMT CAW RJB SED DW ESI PPT.
Contributed reagents/materials/analysis tools: RJB SED CV DW ESI
BLFvES PPT. Wrote the paper: RMT CAW RJB SED CV DW ESI
DMG BLFvES PPT.
1. Szekanecz Z, Koch AE (2007) Macrophages and their products in rheumatoid
arthritis. Curr Opin Rheumatol 19: 289–295.
2. Kinne RW, Stuhlmuller B, Burmester GR (2007) Cells of the synovium in
rheumatoid arthritis. Macrophages. Arthritis Res Ther 9: 224.
Monocyte Scintigraphy in RA
PLoS ONE | www.plosone.org5 November 2009 | Volume 4 | Issue 11 | e7865
3. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, et al. (1997) Analysis of
the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local
disease activity. Arthritis Rheum 40: 217–225.
4. Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, et al. (2004)
Membrane glucocorticoid receptors (mGCR) are expressed in normal human
peripheral blood mononuclear cells and up-regulated after in vitro stimulation
and in patients with rheumatoid arthritis. FASEB J 18: 70–80.
5. Haringman JJ, Gerlag DM, Zwinderman AH, Tak PP (2005) Synovial tissue
macrophages: a sensitive biomarker for response to treatment in patients with
rheumatoid arthritis. Ann Rheum Dis 64: 834–8.
6. Gerlag DM, Haringman JJ, Smeets TJM, Zwinderman AH, Kraan MC, et al.
(2004) Effects of oral prednisolone on biomarkers in synovial tissue and clinical
improvement in rheumatoid arthritis. Arthritis Rheum 50: 3783–91.
7. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP (2003)
Chemokine blockade and chronic inflammatory disease: proof of concept in
patients with rheumatoid arthritis. Ann Rheum Dis 62: 715–21.
8. Taylor PC, Peters AM, Paleolog E, Maini RN (2000) Reduction of chemokine
levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in
patients with rheumatoid arthritis. Arthritis Rheum 43: 38–47.
9. Smeets TJ, Kraan MC, van Loon ME, Tak PP (2003) Tumor necrosis factor
alpha blockade reduces the synovial cell infiltrate early after initiation of
treatment, but apparently not by induction of apoptosis in synovial tissue.
Arthritis Rheum 48: 2155–2162.
10. Wijbrandts CA, Remans PH, Klarenbeek PL, Wouters D, van den Bergh
Weerman M, et al. (2008) Analysis of apoptosis in peripheral blood and synovial
tissue very early after initiation of infliximab treatment in rheumatoid arthritis
patients. Arthritis Rheum 58: 3330–9.
11. Polzer K, Baeten D, Soleiman A, Distler J, Gerlag DM, et al. (2008) TNF
blockade increases lymphangiogenesis in murine and human arthritic joints. Ann
Rheum Dis 67: 1610–6.
12. Loewi G (1969) Experimental immune inflammation in the synovial membrane.
II. The origin and local activity of inflammatory cells. Immunology 17: 489–498.
13. Spector WG, Lykke WJ (1969) The cellular evolution of inflammatory
granulomata. J Path Bac 92: 163–177.
14. Spector WG, Lykke WJ, Willoughby DA (1967) A quantitative study of
leucocyte emigration in chronic inflammatory granulomata. J Path Bact 93:
15. van Furth R (1981) The origin of phagocytic cells in the joint and bone.
Scand J Rheumatol Suppl 40: 13–20.
16. McQueen FM, Ostergaard M (2007) Established rheumatoid arthritis - new
imaging modalities. Best Pract Res Clin Rheumatol 21: 841–856.
17. Braakman E, Schuurhuis GJ, Preijers FW, Voermans C, Theunissen K, et al.
(2008) Evaluation of ‘out-of-specification’ CliniMACS CD34-selection proce-
dures of hematopoietic progenitor cell-apheresis products. Cytotherapy 10:
18. Van Hemert FJ, Thurlings R, Dohmen SE, Voermans C, Tak PP, et al. (2007)
Labeling of autologous monocytes with 99mTc-HMPAO at very high specific
radioactivity. Nucl Med Biol 34: 933–938.
19. Bennink RJ, Thurlings RM, van Hemert FJ, Dohmen SE, van Eck-Smit BL, et
al. (2008) Biodistribution and Radiation Dosimetry of 99mTc-HMPAO Labeled
Monocytes in RA Patients. J Nucl Med 49: 1380–1385.
20. Wijbrandts CA, et al. (2007) The clinical response to infliximab in rheumatoid
arthritis is in part dependent on pretreatment tumour necrosis factor alpha
expression in the synovium. Arthritis Rheum 56: 3869–71.
21. Tak PP (2006) Chemokine inhibition in inflammatory arthritis. Best Pract Res
Clin Rheumatol 20: 929–39.
22. Saravanan V, Hamilton J (2002) Advances in the treatment of rheumatoid
arthritis: old versus new therapies. Expert Opin Pharmacother 3: 845–56.
23. Burman A, Haworth O, Bradfield P, Parsonage G, Filer A, et al. (2005) The role
of leukocyte-stromal interactions in chronic inflammatory joint disease. Joint
Bone Spine 72: 10–6.
24. Chacko M, Weinberg JM (2007) Efalizumab. Dermatol Ther 20: 265–9.
25. Goodin DS, et al. (2008) Assessment: the use of natalizumab (Tysabri) for the
treatment of multiple sclerosis (an evidence-based review): report of the
Therapeutics and Technology Assessment Subcommittee of the American
Academy of Neurology. Neurology 71: 766–73.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 31: 315–24.
27. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et
al. (1995) Modified disease activity scores that include twenty-eight-joint counts.
Development and validation in a prospective longitudinal study of patients with
rheumatoid arthritis. Arthritis Rheum 38: 44–4813.
28. Van Hemert FJ, van Lenthe H, Schimmel KJ, Eck-Smit BL (2005) Preparation,
radiochemical purity control and stability of 99mTc-mertiatide (Mag-3). Ann
Nucl Med 19: 345–9.
29. Wolbink GJ, Bollen J, Baars JW, ten Berge RJ, Swaak AJ, et al. (1993)
Application of a monoclonal antibody against a neoepitope on activated C4 in
an ELISA for the quantification of complement activation via the classical
pathway. J Immunol Methods 163: 67–76.
30. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, et al. (2002) Comparison
of synovial tissues from the knee joints and the small joints of rheumatoid
arthritis patients: Implications for pathogenesis and evaluation of treatment.
Arthritis Rheum 46: 2034–2038.
31. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, et al. (2003)
Analysis of the cell infiltrate and expression of proinflammatory cytokines and
matrix metallopro- teinases in arthroscopic synovial biopsies: comparison with
synovial samples from patients with end stage, destructive rheumatoid arthritis.
Ann Rheum Dis 62: 635–638.
32. Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJ, et al. (1995)
Reduction of synovial inflammation after anti-CD4 monoclonal antibody
treatment in early rheumatoid arthritis. Arthritis Rheum 38: 1457–65.
33. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, et al.
(2005) Reliability of computerized image analysis for the evaluation of serial
synovial biopsies in randomized controlled trials in rheumatoid arthritis.
Arthritis Res Ther 7: R862–R867.
Monocyte Scintigraphy in RA
PLoS ONE | www.plosone.org6 November 2009 | Volume 4 | Issue 11 | e7865